Dr. Jiang is the Senior Vice President of Pharmaceutical Development. He has 20 years of broad experience in drug development and manufacturing from research stage to commercialization.
Prior to joining Aldea Pharmaceuticals‚ Dr. Jiang was a Co-founder and Senior Vice President, Pharmaceutical Development, of Kalidex Pharmaceuticals, a company which developed novel broad-spectrum antibacterials with emphasis on infections caused by drug-resistant gram-negative bacteria. Prior to Kalidex, he was Vice President, Pharmaceutical Chemistry and Process Development of Calixa Therapeutics, and played a key role in the product development and manufacturing of Ceftolozane/Tazobactam, an anti-pseudomonal cephalosporin combination product acquired by Cubist Pharmaceuticals. Prior to Calixa, he was Director of Formulation Development and Head of CMC at Cerexa and played a key role in the product development and manufacturing of Ceftaroline, an anti-MRSA cephalosporin product acquired by Forest laboratories. Prior to Cerexa, he held positions with increasing responsibilities in CMC at Roche Carolina, Roche Palo Alto, and Genesoft Pharamceuticals. Dr. Jiang has a Ph.D. degree in chemistry from Duke University.